Farmas USA

XOMA

Buf, PM ahora mismo a +55%

Edito: +70%

De momento más de un 50% en pre. Enhorabuena a los agraciados.
XOMA

enhorabuena por esas XOMA!

OCAT

Por cierto, el doctor Rose de ese ensayo trabaja o trabajaba para BTX, que ya demostró su inefectividad en su momento y perdió el partening que tenía con una de las grandes, no recuerdo tal. Esá muerta.

Curiosamente, los artículos bajistas de SA de OCAT (excepto el impresentable de MAKO) siempre hablaban de la superioridad de BTX frente a OCAT y siempre hemos sospechado que venían de esa parte.

Tema aparte:
Acaban de publicar dos puestos de trabajo en OCAT

Two Research Associates/Scientists, Cell-based product development ocata jobs

Two Research Associates/Scientists, Cell-based product development
Ocata is seeking two Research Associates/Research Scientists to develop, optimize, and standardize attribute assays for our pluripotent stem cell-derived pipeline products. These positions are an essential component of the larger QC effort driving our IND-enabling studies and involve the design, execution, and/or optimization of various laboratory-based qualitative, quantitative, and mechanistic assays.Laboratory techniques will include: culture and differentiation of pluripotent stem cells, qRT-PCR, immunostaining, flow cytometry, ELISA, cell-based functional assays as well as others.The incumbents will report to the Senior Director of Development and interface with members of the research, quality control, quality assurance, and manufacturing teams.
Major Duties and Responsibilities:

(1)Learn and follow in-house differentiation protocols for desired cell types. Consult with members of cross-functional teams on the potential utility of various attribute assays.
(2)Work as part of a team to identify, test, optimize numerous assays for the characterization of in-process, bulk, and final cell-based products.
(3)Set assay specifications, write/edit standard operating procedures with consultation from relevant members of the research, QC, QA, and manufacturing departments.
(4) QC-validate GMP manufactured lots of pipeline products using SOPS and passing or failing them based on the SOP specifications.
(5)Tighten assay specifications with iterative manufacturing runs, after any process changes, or as product advances through various inflexion points during its clinical development.
Requirements:

B.S./M.S in biology, biochemistry, immunology or related field.
At least 2+ years cell culture experience. Previous experience in one or more of the following areas is a plus: pluripotent stem cell culture, assay development, writing standard operating procedures, validation, GMP documentation
The ability to perform laboratory assays in an accurate and reproducible manner.
Excellent written and oral communication skills.
The ability to work well as a team member.
Authorized to work in the U.S.

PS: David, voy a usar el comodín de la llamada

OCAT

El blog de este hombre es uno de los referentes del campo. Comenta la noticia de la inyección de Pfizer, pero deja claro en el último párrafo que la investigación importante es la de OCAT y menciona también el ensayo de Japón (que se fue a la mierda hace unos meses y al que la mayoría de científicos parecen no verle futuro.)

A todo esto Knoepler, el autor, nunca ha sido trader y hace poco dijo que lleva una posición en una única empresa: OCAT :)

Joooe mugiwara ahi vá,, up , up,up como a los BBs,
Parece que tiene vacante varias plazas de cuidadores de mercado, con el desempleo que hay en España le podemos enviar unos cuantos para que no la dejen volver a bajar mas y SA se ahorre sus repetidos artículos pumpistas
y como ves mas abajo ya me han copiado mi PO
--
Even if DVAX's multiple moves to half of this, then based on the peak sales estimate, DVAX should be valued at around $75.
-
DVAX's ongoing Phase III clinical study of HEPLISAV-B, its Hep B vaccine candidate, is expected to be completed in October. The company is expected to announce top-line results from the trial in early 2016. If results are positive, DVAX's vaccine candidate could be launched by 2017.
If approved HEPLISAV could generate peak sales of $600 million, according to JP Morgan. Based on the current share count of 38.40 million, this translates to $15.62 per share in peak sales.
http://seekingalpha.com/article/3545096-premarket-biotech-digest-biotech-investing-101-dynavaxs-potential-ibb-bounces-back?app=1&auth_param=ft8lg:1b0qa3c:d87fa737c40c98175de7f4bbce0ed463&uprof=37

OCAT

Puesto 34 ayer entre las mayores subidas del Nasdaq

http://www.wsj.com/mdc/public/page/2_3021-gainnnm-gainer.html